Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | HK1 | P19367 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689314 | 0.87 | PDE5A (0.39) | PDE5APDE1BMAOAADORA3ADORA2A | |
| SCHEMBL28493970 | 0.87 | PDE5A (0.39) | PDE5APDE1BADORA3ADORA2AALDH1A1 | |
| SCHEMBL16689304 | 0.87 | HSP90AA1 (0.39) | PDE5APDE1BALDH1A1MAPTKDM4E | |
| SCHEMBL7794238 | 0.84 | PDE5A (0.49) | PDE5APDE1BMAOAALDH1A1MEN1 | |
| SCHEMBL10957300 | 0.84 | YTHDC1 (0.35) | PDE5AADORA3ADORA2AALDH1A1MAPT | |
| SCHEMBL9038418 | 0.83 | PDE5A (0.64) | PDE5APDE1BMAOAKMT2ASMN1; SMN2 | |
| SCHEMBL10955681 | 0.81 | ALDH1A1 (0.49) | PDE5APDE1BADORA3ADORA2AALDH1A1 | |
| SCHEMBL30615164 | 0.81 | ALDH1A1 (0.49) | PDE5APDE1BADORA3ADORA2AALDH1A1 | |
| SCHEMBL856422 | 0.79 | PDE5A (0.68) | PDE5APDE1BALDH1A1MAPTMEN1 | |
| SCHEMBL27296032 | 0.79 | SMN1; SMN2 (0.35) | ALDH1A1MAPTKDM4ECYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | PAMUKCU RIFAT (US) | 2001-10-18 | — | — | US | disclosed |
| US-6262059-B1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | CELL PATHWAYS, INC. | 2001-07-17 | — | — | US | disclosed |
| US-6046206-A | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives | CELL PATHWAYS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801180-A | ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | EISAI CO., LTD. (JP) | 1998-09-01 | — | — | US | disclosed |
| US-5693652-A | Benzimidazoles for ischemic heart conditions | EISAI CO., LTD. (JP) | 1997-12-02 | — | — | US | disclosed |
| US-5576322-A | Anti-ischemic 2,4-diaminoquinazolines | EISAI CO., LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0393574-B1 | Hexitol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-01-31 | — | — | EP | disclosed |
| EP-0607439-A1 | NITROGENOUS HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 1994-07-27 | — | — | EP | disclosed |
| US-5053408-A | Cardiovascular disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4351832-A | 2-(Piperazinyl)-4-pyrimidinamines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-28 | — | — | US | disclosed |
| US-4333937-A | 2-(Piperazinyl)-4-pyrimioinamines | AMERICAN HOME PRODUCTS CORP. (US) | 1982-06-08 | — | — | US | disclosed |
| EP-0039190-A1 | 2-(1-Piperazinyl)-4-pyrimidinamines and related compounds | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-11-04 | — | — | EP | disclosed |
| WO-1981003022-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PROD (US) | 1981-10-29 | — | — | WO | disclosed |
| EP-0056027-A1 | 2-(1-PIPERAZINYL)-4-PYRIMIDINAMINES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-10-29 | — | — | EP | disclosed |
| US-4102885-A | Process for preparing 2,4-dihaloquinazolines | BRISTOL-MYERS COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108614-A1 | Substituted 2-Amino-Quinazolin-4-Cn Compounds for Use in the Treatment of Cns Disorders, Pain, Stroke, Addiction and Epilepsy, their Preparation and Use as Intermediates | CNR2, CNR1, GRIN2C | PDE5A 1306/4885PDE1B 1656/4885MAOA 372/4885 |
| US-20010031760-A1 | Method of treating a patient having precancerous lesions with quinazoline derivatives | MKI67, PCNA, NQO2 | PDE5A 2260/4885PDE1B 2778/4885MAOA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.